Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma

The purpose of this study is to investigate the expression of the epithelial membrane proteins (EMP) 1, 2, and 3 in adrenal gland neoplasm and to explore the broader implications of this. Tissue microarrays were constructed for 132 cases of adrenal cortical neoplasms (ACN) (adrenal cortical adenoma (115 cases), and carcinoma (17 cases)) and 189 cases of pheochromocytoma. Immunohistochemical staining was performed to identify EMP 1, 2, and 3, and was compared with clinicopathological parameters. The H-score of EMP 3 (p < 0.001) was higher in pheochromocytoma when compared to that of ACN, and the H-score of EMP 1 (p < 0.001) and EMP 3 (p < 0.001) was higher in adrenal cortical carcinomas when compared to that of adrenal cortical adenomas. A higher EMP 1 H-score was observed in pheochromocytomas with a GAPP score ≥3 (p = 0.018). In univariate analysis, high levels of EMP 1 and EMP 3 expression in ACN were associated with shorter overall survival (p = 0.001). Differences were observed in the expression of EMPs between ACN and pheochromocytoma. EMPs are associated with malignant tumor biology in adrenal cortical neoplasm and pheochromocytoma, suggesting the role of a prognostic and/or predictive factor for EMPs in adrenal tumor.

[1]  H. Gogas,et al.  Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas , 2023, Oncology research.

[2]  Yang Lu,et al.  Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? , 2022, Cancers.

[3]  D. Fraker,et al.  Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. , 2020, The Journal of clinical endocrinology and metabolism.

[4]  J. Koo,et al.  Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors , 2020, PloS one.

[5]  Hongyu Yang,et al.  High expression of EMP1 predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma , 2020, Oncology letters.

[6]  S. Puglisi,et al.  New perspectives for mitotane treatment of adrenocortical carcinoma. , 2020, Best practice & research. Clinical endocrinology & metabolism.

[7]  J. Phay,et al.  Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma , 2020, Annals of Surgical Oncology.

[8]  M. Berger,et al.  PD-1 Blockade in Advanced Adrenocortical Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Abdulkadir,et al.  Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. , 2019, The Journal of clinical endocrinology and metabolism.

[10]  Youxin Zhou,et al.  EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K‐AKT signaling and CD44 , 2019, Journal of cellular biochemistry.

[11]  Jeffrey E. Lee,et al.  Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma , 2019, Journal of Immunotherapy for Cancer.

[12]  Wenjing Zhou,et al.  Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway , 2019, Oncology reports.

[13]  L. Brunaud,et al.  COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas , 2019, Virchows Archiv.

[14]  T. Giordano,et al.  Somatic mutations in adrenocortical carcinoma with hyperaldosteronism. , 2018, Endocrine-related cancer.

[15]  R. Claus,et al.  Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial , 2018, Journal of Immunotherapy for Cancer.

[16]  Eric Baudin,et al.  European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. , 2018, European journal of endocrinology.

[17]  A. Kawauchi,et al.  Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and Rac1 , 2018, Oncogene.

[18]  L. Erickson Challenges in surgical pathology of adrenocortical tumours , 2018, Histopathology.

[19]  K. Rajapakshe,et al.  ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells , 2018, Investigative ophthalmology & visual science.

[20]  Seung Hun Lee,et al.  Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma , 2017, PloS one.

[21]  N. Chow,et al.  EMP1, EMP 2, and EMP3 as novel therapeutic targets in human cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[22]  Ming-zi Han,et al.  EMP3 is induced by TWIST1/2 and regulates epithelial-to-mesenchymal transition of gastric cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[23]  M. Habra,et al.  Update on adrenocortical carcinoma management and future directions , 2017, Current opinion in endocrinology, diabetes, and obesity.

[24]  A. Lam Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.

[25]  L. Goodglick,et al.  EMP2 is a novel therapeutic target for endometrial cancer stem cells , 2017, Oncogene.

[26]  B. Khoo,et al.  Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas , 2017, Journal of surgical oncology.

[27]  P. Zhang,et al.  EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[28]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[29]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.

[30]  Weiqing Wang,et al.  Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma , 2016, Oncotarget.

[31]  Shun-Fa Yang,et al.  Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway , 2015, Oncotarget.

[32]  Yan-Ze Jin,et al.  Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma , 2015, Journal of pathology and translational medicine.

[33]  T. Choueiri,et al.  Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. , 2015, The Lancet. Oncology.

[34]  C. Haglund,et al.  Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. , 2015, Human pathology.

[35]  H. Ahmed,et al.  Immunohistochemical expression of cytokeratins and epithelial membrane protein 2 in nasopharyngeal carcinoma and its potential implications. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[36]  M. Papotti,et al.  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.

[37]  Gang Zhao,et al.  Association of EMP1 with gastric carcinoma invasion, survival and prognosis. , 2014, International journal of oncology.

[38]  M. Papotti,et al.  CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma , 2014, PloS one.

[39]  M. Lai,et al.  Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. , 2014, The Journal of urology.

[40]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[41]  S. Ito,et al.  Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. , 2014, Endocrine-related cancer.

[42]  Wan-ning Hu,et al.  Epithelial membrane protein 1 negatively regulates cell growth and metastasis in colorectal carcinoma. , 2014, World journal of gastroenterology.

[43]  Y. Lu,et al.  EMP1 inhibits nasopharyngeal cancer cell growth and metastasis through induction apoptosis and angiogenesis , 2014, Tumor Biology.

[44]  Y. Wang,et al.  EMP1 regulates caspase-9 and VEGFC expression and suppresses prostate cancer cell proliferation and invasion , 2014, Tumor Biology.

[45]  M. D. Boer,et al.  EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion , 2014, Leukemia.

[46]  Jonathan Braun,et al.  Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer , 2014, Molecular Cancer Therapeutics.

[47]  Y. Lu,et al.  EMP1, a member of a new family of antiproliferative genes in breast carcinoma , 2014, Tumor Biology.

[48]  S. Pittaluga,et al.  The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. , 2014, The Journal of clinical endocrinology and metabolism.

[49]  C. Wan,et al.  Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. , 2013, Experimental and molecular pathology.

[50]  C. Chai,et al.  Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. , 2013, The American journal of pathology.

[51]  S. Sidhu,et al.  Current management options for recurrent adrenocortical carcinoma , 2013, OncoTargets and therapy.

[52]  H X Chen,et al.  Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma , 2013, British Journal of Cancer.

[53]  L. Goodglick,et al.  EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF , 2013, Oncogene.

[54]  E. Leich,et al.  Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis , 2012, The Journal of clinical endocrinology and metabolism.

[55]  E. Baudin,et al.  Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. , 2012, The Journal of clinical endocrinology and metabolism.

[56]  P. Argani,et al.  Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas. , 2012, Urology.

[57]  G. Scagliotti,et al.  Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer , 2012, Clinical Cancer Research.

[58]  Wen-Ren Wu,et al.  Loss of epithelial membrane protein-2 expression confers an independent prognosticator in nasopharyngeal carcinoma: a cohort study , 2012, BMJ Open.

[59]  M. Papotti,et al.  Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. , 2012, European journal of endocrinology.

[60]  K. Bussey,et al.  Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond , 2011, Hormones & cancer.

[61]  L. Goodglick,et al.  Epithelial Membrane Protein-2 Promotes Endometrial Tumor Formation through Activation of FAK and Src , 2011, PloS one.

[62]  P. Adam,et al.  Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome , 2010, Modern Pathology.

[63]  J. Bertherat,et al.  Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. , 2010, Cancer research.

[64]  S. Horvath,et al.  Epithelial membrane protein‐2 expression is an early predictor of endometrial cancer development , 2010, Cancer.

[65]  F. Beuschlein,et al.  High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.

[66]  L. Goodglick,et al.  Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer , 2010, Clinical Cancer Research.

[67]  M. Papotti,et al.  Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification , 2009, Histopathology.

[68]  Herb Chen,et al.  Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells , 2009, World Journal of Surgery.

[69]  K. Tanimoto,et al.  EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. , 2009, Cancer letters.

[70]  Jinming Yu,et al.  EMP3 Overexpression in Primary Breast Carcinomas is not Associated with Epigenetic Aberrations , 2009, Journal of Korean medical science.

[71]  A. Wu,et al.  Diabodies Targeting Epithelial Membrane Protein 2 Reduce Tumorigenicity of Human Endometrial Cancer Cell Lines , 2008, Clinical Cancer Research.

[72]  H. Kuo,et al.  The Evolving Transcriptome of Head and Neck Squamous Cell Carcinoma: A Systematic Review , 2008, PloS one.

[73]  H. Neumann,et al.  Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma , 2008, Endocrine-related cancer.

[74]  G. Turashvili,et al.  Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. , 2007, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[75]  D. Seligson,et al.  Expression of epithelial membrane protein‐2 is associated with endometrial adenocarcinoma of unfavorable outcome , 2006, Cancer.

[76]  Karel Pacak,et al.  Phaeochromocytoma , 2005, The Lancet.

[77]  S. Shak,et al.  Epithelial membrane protein-1 is a biomarker of gefitinib resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  C. Moskaluk,et al.  Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. , 2005, The American journal of pathology.

[79]  P. Adam,et al.  AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[80]  Miguel Alaminos,et al.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.

[81]  Stuart M. Brown,et al.  Selection and validation of differentially expressed genes in head and neck cancer , 2004, Cellular and Molecular Life Sciences CMLS.

[82]  R. Zeillinger,et al.  Identification of Genes Associated with the Invasive Status of Human Mammary Carcinoma Cell Lines by Transcriptional Profiling , 2003, Tumor Biology.

[83]  Allison Jones,et al.  cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.

[84]  L. Thompson Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.

[85]  L. del Peso,et al.  Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells , 2001, The Journal of Biological Chemistry.

[86]  W. Gerald,et al.  Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  H. Aburatani,et al.  Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. , 2001, Cancer research.

[88]  U. Suter,et al.  Embryonic expression of epithelial membrane protein 1 in early neurons. , 1999, Brain research. Developmental brain research.

[89]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[90]  N. Benvenisty,et al.  Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22. , 1998, Genomics.

[91]  U. Suter,et al.  Identification and characterization of a cDNA and the structural gene encoding the mouse epithelial membrane protein-1. , 1996, Genomics.

[92]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[93]  P. Unger,et al.  S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. , 1991, Archives of pathology & laboratory medicine.

[94]  E. Corssmit,et al.  Malignant pheochromocytoma and paraganglioma: management options. , 2019, Current opinion in oncology.

[95]  A. Ichihara,et al.  Combination Chemotherapy with Cyclophosphamide, Vincristine, and Dacarbazine in Patients with Malignant Pheochromocytoma and Paraganglioma , 2013, Hormones and Cancer.

[96]  J. 晶,et al.  EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway , 2012, Journal of Huazhong University of Science and Technology [Medical Sciences].

[97]  R. Kuick,et al.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[98]  E. Baudin,et al.  Prognostic parameters of metastatic adrenocortical carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[99]  P. Devos,et al.  A Clinicopathologic and Immunohistochemical Study of 49 Adrenocortical Tumors , 2002 .